Open-label trial finds full-spectrum CBD reduced anxiety significantly within one week, with cognitive improvements

Anxiety scores decreased significantly by week 4 (BAI: p<0.001; OASIS: p<0.001). Clinically significant treatment response (≥15% symptom reduction) was achieved by week 1 in 78.6-92.7% of patients and reached 100% by week 3. Secondary outcomes including mood, sleep, quality of life, and executive function also improved. The study drug was well-tolerated with minor side effects (sleepiness, increased energy, dry mouth).

Open-label stage of clinical trial NCT02548559. 14 outpatients with moderate-to-severe anxiety (BAI ≥16 or OASIS ≥11) received 1 mL t.i.d. of a full-spectrum high-CBD sublingual solution (9.97 mg/mL CBD, 0.23 mg/mL THC) for 4 weeks. Autoregressive linear modeling assessed outcomes.

This is one of the first clinical trials to examine cognitive outcomes alongside anxiety outcomes with a CBD product, and the finding that executive function improved (rather than deteriorated) addresses a key safety concern.

The rapid onset of anxiety reduction (within one week) and improvement in cognitive function distinguish this full-spectrum CBD product from both traditional anxiolytics (which may take weeks) and THC-containing products (which may impair cognition).

Open-label design without placebo control. Very small sample (n=14). Short duration (4 weeks). Full-spectrum product contains trace THC and other compounds. Cannot attribute effects to CBD alone. Double-blind stage ongoing.